Michal Bista

Michal Bista

Auto-generated profile, based on publicly available information

Michal Bista

Captor Therapeutics Inc. Wrocław Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JKJason G. Kettle
Jason G. Kettle
HAHusam Alwan
Husam Alwan
MBMichal Bista
Michal Bista
JBJason Breed
Jason Breed
NDNichola L. Davies
Nichola L. Davies
MWMarta Wylot
Marta Wylot
Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the “housekeeping” enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.

20 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
FRFernando Orden Rueda
Fernando Orden Rueda
MBMichal Bista
Michal Bista
MNMatthew D. Newton
Matthew D. Newton
AGAnne U. Goeppert
Anne U. Goeppert
MCM. Emanuela Cuomo
M. Emanuela Cuomo
BTBenjamin J. M. Taylor
Benjamin J. M. Taylor
The CRISPR–Cas9 RNA-guided endonuclease system allows precise and efficient modification of complex genomes and is continuously developed to enhance specificity, alter targeting and add new functional moieties. However, one area yet to be explored is the base chemistry of the associated RNA molecules. Here we show the design and optimisation of hybrid DNA–RNA CRISPR and tracr molecules based on structure-guided approaches. Through careful mapping of the ribose requirements of Cas9, we develop hybrid versions possessing minimal RNA residues, which are sufficient to direct specific nuclease activity in vitro and in vivo with reduced off-target activity. We identify critical regions within these molecules that require ribose nucleotides and show a direct correlation between binding affinity/stability and cellular activity. This is the first demonstration of a non-RNA-guided Cas9 endonuclease and first step towards eliminating the ribose dependency of Cas9 to develop a XNA-programmable endonuclease.

1 December 2013 in Structure
Verified
Journal Article
Closed access
MBMichal Bista
Michal Bista
SWSiglinde Wolf
Siglinde Wolf
KKKareem Khoury
Kareem Khoury
KKKaja Kowalska
Kaja Kowalska
YHYijun Huang
Yijun Huang
ADAlexander Dömling
Alexander Dömling

14 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MBMichal Bista
Michal Bista
MPMiriana Petrovich
Miriana Petrovich
AFAlan R. Fersht
Alan R. Fersht
Significance: The protein MDMX is an important negative regulator of the tumor suppressor p53 in normal cells and can become a powerful oncogene. Previous studies on isolated protein fragments established that the N-terminal domain of MDMX binds tightly to the N-terminal domain of p53 and inhibits it. We now find that full-length MDMX contains a regulatory element (the “WWW element”) that binds to its own N-terminal domain and prevents MDMX from binding to p53. This autoinhibition introduces a new level of regulation of MDMX, whereby accessory proteins may sequester the WWW sequence and reactivate MDMX, and may explain why a variant of MDMX that lacks the WWW sequence, which is found in some cancer cells, might be oncogenic.

1 February 2019 in SLAS Discovery
Verified
Journal Article
Open access
JSJoseph Shaw
Joseph Shaw
IDIan Dale
Ian Dale
PHPaul Hemsley
Paul Hemsley
LLLindsey Leach
Lindsey Leach
NDNancy Dekki
Nancy Dekki
DGDavide Gianni
Davide Gianni
Methods to measure cellular target engagement are increasingly being used in early drug discovery. The Cellular Thermal Shift Assay (CETSA) is one such method. CETSA can investigate target engagement by measuring changes in protein thermal stability upon compound binding within the intracellular environment. It can be performed in high-throughput, microplate-based formats to enable broader application to early drug discovery campaigns, though high-throughput forms of CETSA have only been reported for a limited number of targets. CETSA offers the advantage of investigating the target of interest in its physiological environment and native state, but it is not clear yet how well this technology correlates to more established and conventional cellular and biochemical approaches widely used in drug discovery. We report two novel high-throughput CETSA (CETSA HT) assays for B-Raf and PARP1, demonstrating the application of this technology to additional targets. By performing comparative analyses with other assays, we show that CETSA HT correlates well with other screening technologies and can be applied throughout various stages of hit identification and lead optimization. Our results support the use of CETSA HT as a broadly applicable and valuable methodology to help drive drug discovery campaigns to molecules that engage the intended target in cells.

21 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JNJ. Willem M. Nissink
J. Willem M. Nissink
MBMichal Bista
Michal Bista
JBJason Breed
Jason Breed
NCNikki Carter
Nikki Carter
KEKevin Embrey
Kevin Embrey
JWJon J. Winter-Holt
Jon J. Winter-Holt
MTH1 (NUDT1) is an oncologic target involved in the prevention of DNA damage. We investigate the way MTH1 recognises its substrates and present substrate-bound structures of MTH1 for 8-oxo-dGTP and 8-oxo-rATP as examples of novel strong and weak binding substrate motifs. Investigation of a small set of purine-like fragments using 2D NMR resulted in identification of a fragment with weak potency. The protein-ligand X-Ray structure of this fragment provides insight into the role of water molecules in substrate selectivity. Wider fragment screening by NMR resulted in three new protein structures exhibiting alternative binding configurations to the key Asp-Asp recognition element of the protein. These inhibitor binding modes demonstrate that MTH1 employs an intricate yet promiscuous mechanism of substrate anchoring through its Asp-Asp pharmacophore. The structures suggest that water-mediated interactions convey selectivity towards oxidized substrates over their non-oxidised counterparts, in particular by stabilization of a water molecule in a hydrophobic environment through hydrogen bonding. These findings may be useful in the design of inhibitors of MTH1.